Methylation of PTEN as a prognostic factor in malignant melanoma of the skin

Journal of Investigative Dermatology

Volumn 130, Issue 2, 2010, Pages 620-622

  Lahtz, Christoph ^a   Stranzenbach, René ^b   Fiedler, Eckhard ^b   Helmbold, Peter ^c   Dammann, Reinhard H ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P16; RAF PROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RAS PROTEIN;

AMINO ACID SUBSTITUTION; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DNA METHYLATION; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LETTER; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; TUMOR LOCALIZATION;

EID: 75549087174     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2009.226     Document Type: Letter

References (10)

1. Akslen LA, Angelini S, Straume O, Bachmann IM, Molven A, Hemminki K et al. (2005) BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol 125:312-317
2. Besaratinia A, Pfeifer GP (2008) Sunlight ultraviolet irradiation and BRAF V600 mutagenesis in human melanoma. Hum Mutat 29:983-991
3. Furuta J, Umebayashi Y, Miyamoto K, Kikuchi K, Otsuka F, Sugimura T et al. (2004) Promoter methylation profiling of 30 genes in human malignant melanoma. Cancer Sci 95:962-968
4. Helmbold P, Lautenschlager C, Marsch W, Nayak RC (2006) Detection of a physiological juvenile phase and the central role of pericytes in human dermal micro-vascular aging. J Invest Dermatol 126: 1419-1421
5. Mikhail M, Velazquez E, Shapiro R, Berman R, Pavlick A, Sorhaindo L et al. (2005) PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin Cancer Res 11: 5153-5157
6. Mirmohammadsadegh A, Marini A, Nambiar S, Hassan M, Tannapfel A, Ruzicka T et al. (2006) Epigenetic silencing of the PTEN gene in melanoma. Cancer Res 66:6546-6552
7. Reifenberger J, Knobbe CB, Sterzinger AA, Blas-chke B, Schulte KW, Ruzicka T et al. (2004) Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer 109:377-384
8. Schagdarsurengin U, Gimm O, Dralle H, Hoang-Vu C, Dammann R (2006) CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. Thyroid 16:633-642
9. Zhou XP, Gimm O, Hampel H, Niemann T, Walker MJ, Eng C (2000) Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 157:1123-1128
10. Zysman MA, Chapman WB, Bapat B (2002) Considerations when analyzing the methyla-tion status of PTEN tumor suppressor gene. Am J Pathol 160:795-800